We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+8.43%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$5.25B
AUM Growth
+$451M
Cap. Flow
+$312M
Cap. Flow %
5.94%
Top 10 Hldgs %
53.61%
Holding
70
New
10
Increased
19
Reduced
1
Closed
8

Top Buys

Rank Stock Value
1
BRKR icon
Bruker
BRKR
+$135M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$106M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$60M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.6M
5
ISRG icon
Intuitive Surgical
ISRG
+$51.4M

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$351M
2
VTYX
Ventyx Biosciences
VTYX
+$46.5M
3
APYX icon
Apyx Medical
APYX
+$8.21M
4
ALLK
Allakos
ALLK
+$5.9M
5
CSTL icon
Castle Biosciences
CSTL
+$5.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIST icon
51
Milestone Pharmaceuticals
MIST
$152M
$9.28M 0.18%
3,256,102
– –
APYX icon
52
Apyx Medical
APYX
$171M
$8.94M 0.17%
1,777,194
-1,621,085
-48% -$8.21M
URGN icon
53
UroGen Pharma
URGN
$2.29B
$8.87M 0.17%
857,464
– –
BDTX icon
54
Black Diamond Therapeutics
BDTX
$112M
$8.59M 0.16%
+1,700,000
New +$3.47M
DMTK
55
DELISTED
DermTech, Inc. Common Stock
DMTK
$7.07M 0.13%
2,718,356
– –
RLMD icon
56
Relmada Therapeutics
RLMD
$527M
$5.24M 0.1%
2,131,835
– –
XGN icon
57
Exagen
XGN
$166M
$4.33M 0.08%
1,492,432
+101,248
+7% +$288K
AKYA
58
DELISTED
Akoya BioSciences
AKYA
$2.5M 0.05%
338,422
+10,000
+3% +$66.8K
MRSN
59
DELISTED
Mersana Therapeutics
MRSN
$2.02M 0.04%
+24,594
New +$3.6M
ARYD
60
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.35M 0.03%
127,970
– –
MIRO
61
DELISTED
Miromatrix Medical Inc. Common Stock
MIRO
$779K 0.01%
445,222
– –
RCKTW icon
62
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$66.5K ﹤0.01%
350,000
– –
ALLK
63
DELISTED
Allakos
ALLK
– –
-1,326,608
Closed -$5.9M
CSTL icon
64
Castle Biosciences
CSTL
$979M
– –
-258,498
Closed -$5.87M
JSPR icon
65
Jasper Therapeutics
JSPR
$23.6M
– –
-232,981
Closed -$4.22M
SGHT icon
66
Sight Sciences
SGHT
$412M
– –
-41,330
Closed -$361K
THRD
67
DELISTED
Third Harmonic Bio
THRD
– –
-534,687
Closed -$2.2M
VTYX
68
DELISTED
Ventyx Biosciences
VTYX
– –
-1,388,881
Closed -$46.5M
LSB
69
DELISTED
LakeShore Biopharma
LSB
– –
-34,109
Closed -$546K
RXDX
70
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-3,272,104
Closed -$351M
1 2
3

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q2 2023 Portfolio in Review

As of Q2 2023, RTW Investments held 70 positions worth $5.25B, up 9.4% from $4.8B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RTW Investments deployed $312M of net new capital in Q2 2023, opening 10 new positions and adding to 19 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Apyx Medical, an estimated $8.21M trimmed.

  • RTW Investments's largest Q2 2023 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,000,000 shares worth $103M.
  • RTW Investments added most to Bruker in Q2 2023, an estimated $135M increase.
  • RTW Investments's biggest Q2 2023 reduction was Apyx Medical, cutting an estimated $8.21M.
  • RTW Investments fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $351M.
  • RTW Investments's ten largest holdings make up 54% of its $5.25B portfolio in Q2 2023.
  • RTW Investments opened 10 new positions and closed 8 in Q2 2023.
  • RTW Investments's portfolio value rose 9.4% quarter-over-quarter to $5.25B.

Based on RTW Investments's 13F filing for Q2 2023, filed 14 Aug 2023.